40
Participants
Start Date
January 19, 2018
Primary Completion Date
April 12, 2019
Study Completion Date
June 30, 2019
Normal Saline along with standard treatment
The arm is for active comparison for PMZ-1620 (sovateltide), an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients. Normal saline (vehicle) with standard treatment will be provided.
PMZ-1620 along with standard treatment
PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients.
All India Institute of Medical Sciences, New Delhi
Paras Hospital, Gūrgaon
Dayanand Medical College & Hospital, Ludhiana
Department of Neurology, Christian Medical College and Hospital, Ludhiana
Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow
New Era Hospital & Research Institute, Nagpur
Nizam's Institute of Medical Sciences, Hyderabad
Lead Sponsor
Pharmazz, Inc.
INDUSTRY